Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes

    Access Status
    Fulltext not available
    Authors
    Mooranian, Armin
    Zamani, Nassim
    Takechi, Ryu
    Al-Sallami, H.
    Mikov, M.
    Golocorbin-Kon, S.
    Kovacevic, B.
    Arfuso, Frank
    Al-Salami, Hani
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Mooranian, A. and Zamani, N. and Takechi, R. and Al-Sallami, H. and Mikov, M. and Golocorbin-Kon, S. and Kovacevic, B. et al. 2018. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine and Biotechnology. 46 (Suppl. 3): pp. S748-S754.
    Source Title
    Artificial Cells, Nanomedicine and Biotechnology
    DOI
    10.1080/21691401.2018.1511572
    ISSN
    2169-141X
    School
    School of Pharmacy and Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/72017
    Collection
    • Curtin Research Publications
    Abstract

    INTRODUCTION: The ratio of secondary to primary bile acids changes during Type 1 Diabetes (T1D) development and these effects might be ameliorated by using cholesterol lowering drugs or hydrophilic bile acids. Probucol is a cholesterol-lowering drug, while ursodeoxycholic acid is a hydrophilic bile acid. This study investigated whether nanoencapsulated probucol with ursodeoxycholic acid altered bile acid ratios and the development of diabetes. METHODS: Balb/c mice were divided into three groups and gavaged daily with either free probucol, nanoencapsulated probucol or nanoencapsulated probucol with ursodeoxycholic acid for seven days. Alloxan was injected and once T1D was confirmed the mice continued to receive daily gavages until euthanasia. Blood, tissues, faeces and urine were collected for analysis of insulin and bile acids. RESULTS AND CONCLUSIONS: Nanoencapsulated probucol-ursodeoxycholic acid resulted in significant levels of insulin in the blood, lower levels of secondary bile acids in liver and lower levels of primary bile acids in brain, while ratio of secondary to primary bile acids remains similar among all groups, except in the faeces. Findings suggests that nanoencapsulated probucol-ursodeoxycholic acid may exert a protective effect on pancreatic ß-cells and reserve systemic insulin load via modulation of bile acid concentrations in the liver and brain.

    Related items

    Showing items related by title, author, creator and subject.

    • The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects
      Mooranian, Armin; Negrulj, Rebecca; Takechi, Ryu; Mamo, John; Al-Sallami, H.; Al-Salami, Hani (2018)
      Probucol (PB) is an hypolipidaemic drug with potential antidiabetic effects. We showed recently using in vitro studies that when PB was incorporated with stabilising lipophilic bile acids and microencapsulated using the ...
    • The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
      Mathavan, Sangeetha (2017)
      Gliclazide is used in Type 2 diabetes (T2D) to stimulate insulin production but it also has beneficial extra-pancreatic effects which make it potentially useful in T1D. In this thesis, gliclazide was formulated with ...
    • An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques
      Mooranian, Armin ; Zamani, Nassim; Takechi, Ryu ; Luna, Giuseppe; Mikov, M.; Goločorbin-Kon, S.; Elnashar, Magdy ; Arfuso, Frank; Al-Salami, Hani (2019)
      © 2019 Mooranian et al. Type 2 diabetes (T2D) is characterised by β-cell damage and hyperglycaemia. The lipophilic drug, probucol, has shown significant β-cell protective and potential antidiabetic effects, which were ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.